Amicus Therapeutics, Inc.
FOLD
Rang în acțiuni
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Preț acțiune
$14.49
Ultima sincronizare: 2026-04-27
Capitalizare de piață
$4.55B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
80.22%
Țară
US
Tranzacționează Amicus Therapeutics, Inc. (FOLD)
Categorie
Healthcare
EPS pentru Amicus Therapeutics, Inc. (FOLD)
EPS la data de December 2025 TTM: $-0.09
Conform celor mai recente rapoarte financiare și prețului acțiunilor Amicus Therapeutics, Inc., EPS-ul actual al companiei (TTM) este $-0.09. La sfârșitul anului 2023, compania avea un EPS de $-0.51 o scădere comparativ cu EPS-ului din 2022, care a fost de $-0.82.
Istoricul EPS pentru Amicus Therapeutics, Inc. din 2003 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-0.09 | -50.83% |
| 2024 | $-0.18 | -64.71% |
| 2023 | $-0.51 | -37.80% |
| 2022 | $-0.82 | -10.87% |
| 2021 | $-0.92 | -14.02% |
| 2020 | $-1.07 | -27.70% |
| 2019 | $-1.48 | -21.28% |
| 2018 | $-1.88 | 1.62% |
| 2017 | $-1.85 | 24.16% |
| 2016 | $-1.49 | 24.17% |
| 2015 | $-1.20 | 29.03% |
| 2014 | $-0.93 | -19.83% |
| 2013 | $-1.16 | 8.41% |
| 2012 | $-1.07 | -16.41% |
| 2011 | $-1.28 | -35.35% |
| 2010 | $-1.98 | 582.76% |
| 2009 | $-0.29 | -83.43% |
| 2008 | $-1.75 | -43.73% |
| 2007 | $-3.11 | -95.06% |
| 2006 | $-62.97 | 29.33% |
| 2005 | $-48.69 | 70.01% |
| 2004 | $-28.64 | 30.12% |
| 2003 | $-22.01 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -19,670.62% |
US
|
|
| $-7.98 | 8,916.95% |
US
|
|
| $-5.29 | 5,877.40% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -31,444.63% |
NL
|
